Detailed View
SPRY - ARS Pharmaceuticals, Inc.
Latest filing: 2026-03-31 | Reporting: gaap
Market Cap
601,777,792
Adj EBIT (TTM)
-202,416,000
Enterprise Value
400,808,792
Last Price
6.06
Earnings Yield
-50.50%
Return on Capital
-90.45%
Capital
223,783,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2026 | 22,681,000 | -60,145,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 28,087,000 | -41,465,000 |
| 2025-09-30 | 10-Q | 2025 | 32,501,000 | -53,192,000 |
| 2025-06-30 | 10-Q | 2025 | 15,717,000 | -47,614,000 |
| 2025-03-31 | 10-Q | 2025 | 7,973,000 | -37,177,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 86,581,000 | 47,197,000 |
| 2024-09-30 | 10-Q | 2024 | 2,068,000 | -21,748,000 |
| 2024-06-30 | 10-Q | 2024 | 500,000 | -15,340,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.